The FDA authorized neoadjuvant Imfinzi, gemcitabine and cisplatin, adopted by adjuvant Imfinzi after radical cystectomy in muscle invasive bladder most cancers.The U.S. Meals...
For adults with PSMA+ metastatic castration-resistant prostate most cancers beforehand handled with androgen receptor inhibitors, the FDA expands Pluvicto indication.The U.S. Meals and...
Sensei Biotherapeutics experiences preliminary knowledge from a section 1/2 trial of solnerstotug in PD-L1-resistant tumors.Sensei Biotherapeutics publicizes favorable preliminary outcomes from the dose...
